FDA Rejects Pair Of Gilead HIV Drugs
Gilead Sciences Inc. said Monday that the Food and Drug Administration rejected its applications to market two HIV treatment drugs, elvitegravir and cobicistat, as standalone drugs, because of problems with quality-testing...To view the full article, register now.
Already a subscriber? Click here to view full article